EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK / PD Modeling

Robin Thomas Ulrich Haid iD, Andreas Reichel iD

Clinical Pharmacology & Therapeutics · 2024-09 · 116 (3) · 770-781

DOI: 10.1002/cpt.3273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 06.05.2024. Verfasst von Robin Thomas Ulrich Haid und 1 weiteren Autor:innen. Beteiligte Einrichtung: Preclinical Modeling & Simulation, Drug Metabolism & Pharmacokinetics, Preclinical Development, Bayer AG, Berlin, Germany. Hauptthemen laut MEDLINE: Models, Biological, Proteolysis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degraders (TPDs), an emerging therapeutic modality, are attracting considerable interest with the promise to address disease‐related proteins that are not druggable with conventional small molecule inhibitors. Despite their novel mechanism of action, the PK/PD relationship of degraders is still approached with a mindset deeply rooted in inhibitor drugs. Here, we establish how predictive mechanistic modeling specifically tailored to TPDs can significantly enhance the value of the available information during lead generation and optimization. By integrating the results from in vitro assays with routinely collected PK data, modeling accurately predicts degradation in vivo . These predictions transform the prioritization of compounds for in vivo studies as well as the selection of optimal dose schedules and most informative measurement time points with the least number of animals. Moreover, the comprehensive modeling framework (1) identifies the PK/PD driver of targeted protein degradation and subsequent downstream pharmacodynamic effects, and (2) uncovers the fundamental difference between degrader and inhibitor PK/PD relationships. The practical utility of our predictive modeling is demonstrated with relevant use cases. This framework will allow researchers to transition from current, mostly serendipity‐based approaches to more sound model‐informed decision making. Going forward, the presented predictive PK/PD modeling framework lays out a rational path to incorporate inter‐species differences in the pharmacology and thus promises to help with getting the dose right in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalProteolysisHumansAnimalsDrug DiscoveryProteins

Substanzen

Proteins

Autor:innen und Institutionen

  • Preclinical Modeling & Simulation, Drug Metabolism & Pharmacokinetics, Preclinical Development, Bayer AG, Berlin, Germany.
  • Biopharmacy, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.

ORCID-Profile: Robin Thomas Ulrich Haid, Andreas Reichel

Zitieren

APA

Haid, R. T. U., & Reichel, A. (2024). Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK / PD Modeling. Clinical Pharmacology & Therapeutics, 116(3), 770-781. https://doi.org/10.1002/cpt.3273

Vancouver

Haid RTU, Reichel A. Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK / PD Modeling. Clinical Pharmacology & Therapeutics. 2024;116(3):770-781. doi:10.1002/cpt.3273

BibTeX
@article{Haid2024,
  author = {Haid, Robin Thomas Ulrich and Reichel, Andreas},
  title = {Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK / PD Modeling},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {116},
  number = {3},
  pages = {770--781},
  doi = {10.1002/cpt.3273}
}
Kostenlos starten →